{"id":152208,"date":"2020-11-19T05:11:48","date_gmt":"2020-11-19T10:11:48","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/todos-medical-announces-positive-initial-clinical-proof-of-concept-data-for-a-rapid-sars-cov-2-3cl-protease-detection-assay\/"},"modified":"2024-08-18T11:41:59","modified_gmt":"2024-08-18T15:41:59","slug":"todos-medical-announces-positive-initial-clinical-proof-of-concept-data-for-a-rapid-sars-cov-2-3cl-protease-detection-assay","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/todos-medical-announces-positive-initial-clinical-proof-of-concept-data-for-a-rapid-sars-cov-2-3cl-protease-detection-assay.php","title":{"rendered":"Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay"},"content":{"rendered":"<p><![CDATA[NEW YORK, NY, REHOVAT, ISRAEL,\u00a0SINGAPORE, Nov.  18, 2020  (GLOBE NEWSWIRE) -- via NewMediaWire\u00a0--\u00a0Todos Medical (OTCQB: TOMDF), an\u00a0in vitro\u00a0diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for early detection of cancer and Alzheimer\u2019s disease, today announced positive clinical proof of concept data from its lab-based rapid SARS-CoV-2 3CL protease diagnostic assay in collaboration with its COVID Antigen Test Killer LLC joint venture partner NLC Pharma. The data generated by NLC Pharma in Israel produced 100% sensitivity and 100% specificity in PCR-confirmed positive and negative COVID-19 patient samples. The team is now gathering additional clinical data to submit an emergency use authorization (EUA) to the United States Food & Drug Administration ( FDA) for its lab-based test to be distributed through Todos\u2019 existing lab distribution channels.\u00a0 Todos is evaluating the best option for the commercialization of its rapid point-of-care version of the 3CL protease assay for the screening and diagnosis of symptomatic and asymptomatic COVID-19 carriers, based on recent updated guidance from the FDA for COVID-19 diagnostic point of care tests.]]><\/p>\n<p>See the original post:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2020\/11\/18\/2129227\/0\/en\/Todos-Medical-Announces-Positive-Initial-Clinical-Proof-of-Concept-Data-for-a-Rapid-SARS-CoV-2-3CL-Protease-Detection-Assay.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay\">Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>See the original post: Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/todos-medical-announces-positive-initial-clinical-proof-of-concept-data-for-a-rapid-sars-cov-2-3cl-protease-detection-assay.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-152208","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/152208"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=152208"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/152208\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=152208"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=152208"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=152208"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}